Free Trial

Repare Therapeutics (RPTX) Competitors

Repare Therapeutics logo
$3.35
-0.10 (-2.90%)
(As of 10/31/2024 ET)

RPTX vs. BDTX, STOK, NGNE, ORIC, NUVB, QTTB, ALMS, AURA, SLN, and CRVS

Should you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Black Diamond Therapeutics (BDTX), Stoke Therapeutics (STOK), Neurogene (NGNE), ORIC Pharmaceuticals (ORIC), Nuvation Bio (NUVB), Q32 Bio (QTTB), Alumis (ALMS), Aura Biosciences (AURA), Silence Therapeutics (SLN), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

Repare Therapeutics vs.

Repare Therapeutics (NASDAQ:RPTX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.

Black Diamond Therapeutics has lower revenue, but higher earnings than Repare Therapeutics. Repare Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare Therapeutics$68.68M2.07-$93.80M-$1.10-3.05
Black Diamond TherapeuticsN/AN/A-$82.44M-$1.50-1.83

Black Diamond Therapeutics received 10 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 69.44% of users gave Black Diamond Therapeutics an outperform vote while only 64.52% of users gave Repare Therapeutics an outperform vote.

CompanyUnderperformOutperform
Repare TherapeuticsOutperform Votes
40
64.52%
Underperform Votes
22
35.48%
Black Diamond TherapeuticsOutperform Votes
50
69.44%
Underperform Votes
22
30.56%

Black Diamond Therapeutics has a net margin of 0.00% compared to Repare Therapeutics' net margin of -99.76%. Repare Therapeutics' return on equity of -31.11% beat Black Diamond Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Repare Therapeutics-99.76% -31.11% -26.39%
Black Diamond Therapeutics N/A -69.08%-51.68%

Repare Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 198.51%. Black Diamond Therapeutics has a consensus price target of $15.50, indicating a potential upside of 465.69%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Repare Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repare Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Black Diamond Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Repare Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500.

In the previous week, Repare Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 3 mentions for Repare Therapeutics and 2 mentions for Black Diamond Therapeutics. Repare Therapeutics' average media sentiment score of 0.67 beat Black Diamond Therapeutics' score of 0.45 indicating that Repare Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Repare Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Black Diamond Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

85.1% of Repare Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 21.6% of Repare Therapeutics shares are held by insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Repare Therapeutics and Black Diamond Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.

Get Repare Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RPTX vs. The Competition

MetricRepare TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$142.19M$7.12B$5.36B$8.41B
Dividend YieldN/A8.77%5.22%4.20%
P/E Ratio-2.0416.06131.9317.57
Price / Sales2.07258.281,440.1578.36
Price / CashN/A50.1639.0633.56
Price / Book0.675.674.744.57
Net Income-$93.80M$151.16M$115.43M$225.42M
7 Day Performance-0.59%-1.80%-0.86%-0.61%
1 Month Performance-2.62%5.92%3.61%1.50%
1 Year Performance-1.47%39.97%38.90%32.94%

Repare Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RPTX
Repare Therapeutics
3.1776 of 5 stars
$3.35
-2.9%
$10.00
+198.5%
+7.1%$142.19M$68.68M-2.04180
BDTX
Black Diamond Therapeutics
2.1872 of 5 stars
$2.92
-2.0%
$15.50
+430.8%
+58.6%$164.26MN/A-1.9590Upcoming Earnings
Short Interest ↑
STOK
Stoke Therapeutics
3.8458 of 5 stars
$12.31
+3.4%
$20.83
+69.2%
+250.1%$620.76M$15.16M-5.65100Upcoming Earnings
Positive News
NGNE
Neurogene
1.763 of 5 stars
$45.93
-5.0%
$51.00
+11.0%
N/A$596.17M$925,000.000.0090
ORIC
ORIC Pharmaceuticals
4.3193 of 5 stars
$8.45
+3.7%
$18.00
+113.0%
+47.9%$596.06MN/A-4.8380Upcoming Earnings
Analyst Forecast
News Coverage
Gap Up
NUVB
Nuvation Bio
3.8038 of 5 stars
$2.35
+6.3%
$6.40
+172.9%
+134.9%$584.47MN/A-1.1160Upcoming Earnings
QTTB
Q32 Bio
1.9151 of 5 stars
$46.74
-7.6%
$72.33
+54.8%
N/A$563.68M$1.16M-2.0339News Coverage
ALMS
Alumis
N/A$11.99
+0.8%
$28.00
+133.5%
N/A$559.08MN/A0.00N/AAnalyst Forecast
AURA
Aura Biosciences
3.8492 of 5 stars
$10.98
+0.5%
$23.00
+109.5%
+38.7%$543.98MN/A-6.1350Short Interest ↓
SLN
Silence Therapeutics
2.8674 of 5 stars
$18.07
-0.1%
$57.20
+216.5%
+147.4%$540.84M$31.55M-14.81100
CRVS
Corvus Pharmaceuticals
1.7416 of 5 stars
$8.64
+4.0%
$10.83
+25.4%
+714.8%$540.44MN/A-19.2030Upcoming Earnings
Analyst Downgrade
Short Interest ↑
News Coverage
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:RPTX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners